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Abstract
Background: Colorectal cancer is a heterogeneous disease arising from at least two precursors—the conventional
adenoma (CA) and the serrated polyp. We and others have previously shown a relationship between the human gut
microbiota and colorectal cancer; however, its relationship to the different early precursors of colorectal cancer is
understudied. We tested, for the first time, the relationship of the gut microbiota to specific colorectal polyp types.
Results: Gut microbiota were assessed in 540 colonoscopy-screened adults by 16S rRNA gene sequencing of stool
samples. Participants were categorized as CA cases (n= 144), serrated polyp cases (n= 73), or polyp-free controls (n= 323).
CA cases were further classified as proximal (n= 87) or distal (n= 55) and as non-advanced (n= 121) or advanced (n= 22).
Serrated polyp cases were further classified as hyperplastic polyp (HP; n= 40) or sessile serrated adenoma (SSA; n= 33). We
compared gut microbiota diversity, overall composition, and normalized taxon abundance among these groups.
CA cases had lower species richness in stool than controls (p= 0.03); in particular, this association was strongest for
advanced CA cases (p= 0.004). In relation to overall microbiota composition, only distal or advanced CA cases differed
significantly from controls (p= 0.02 and p= 0.002). In taxon-based analysis, stool of CA cases was depleted in a network of
Clostridia operational taxonomic units from families Ruminococcaceae, Clostridiaceae, and Lachnospiraceae, and enriched in
the classes Bacilli and Gammaproteobacteria, order Enterobacteriales, and genera Actinomyces and Streptococcus (all q< 0.10).
SSA and HP cases did not differ in diversity or composition from controls, though sample size for these groups was small.
Few taxa were differentially abundant between HP cases or SSA cases and controls; among them, class Erysipelotrichi was
depleted in SSA cases.
Conclusions: Our results indicate that gut microbes may play a role in the early stages of colorectal carcinogenesis
through the development of CAs. Findings may have implications for developing colorectal cancer prevention therapies
targeting early microbial drivers of colorectal carcinogenesis.
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Background
Colorectal cancer (CRC) is the third most common
cancer and fourth most common cause of cancer death
worldwide [1]. CRC represents a heterogeneous group of
cancers arising through different combinations of
genetic and epigenetic events [2]: the “conventional”
pathway to CRC is characterized by adenomatous
polyposis coli (APC) mutation, chromosomal instability,
and paucity of CpG island hypermethylation, while the
“serrated” pathway is characterized by B-Raf proto-
oncogene, serine/threonine kinase (BRAF) mutation,
chromosomal stability, and high CpG island hyperme-
thylation [3]. The majority of CRC cases (~60%) arise via
the “conventional” pathway, with ~20% arising from the
“serrated” pathway and ~20% arising from an alternate
pathway [4]. These distinct molecular pathways originate
with different precursor lesions: the “conventional”
pathway with conventional adenomas (CAs) and the
“serrated” pathway with sessile serrated adenomas
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(SSAs) [4]. An additional serrated polyp type, the hyper-
plastic polyp (HP), has negligible malignant potential [2].
Different polyp types also have tendencies to present in
specific colorectal locations [2, 5].
Mounting evidence implicates gut bacteria as causal
players in colorectal carcinogenesis [6], though their dis-
tinct contributions through CAs or SSAs have not been
examined simultaneously. Stool transplant experiments
from colon tumor-bearing mice or human CRC patients
to germ-free mice have revealed a critical role of the gut
microbiota in CRC development [7, 8]. Additionally,
studies in humans, including a study by our group [9],
have associated mucosal or stool microbiota composition
with presence of colorectal polyps or CRC [6]. Recently,
greater attention has been focused on characterizing the
gut microbiota across different stages of colorectal
carcinogenesis [10, 11], to better distinguish bacteria con-
tributing to CRC initiation (“driver” bacteria) from bac-
teria proliferating as a result of CRC (“passenger” bacteria)
[12]. Microbes and their metabolites have been proposed
to promote carcinogenesis by several mechanisms, includ-
ing induction of inflammatory signaling pathways, genetic
mutations, and epigenetic dysregulation [13–15]. Because
CRC arises along different molecular pathways from spe-
cific precursor lesions at specific colorectal sites, it is pos-
sible that different bacteria are involved in each pathway
and associated with each precursor type and/or location;
however, no studies have characterized the gut microbiota
of colorectal polyp cases according to histologic type and
location.
Here, we characterize the microbiota of stool samples
from 540 colonoscopy-screened individuals. Detailed en-
doscopy and pathology reports allowed us to classify
these individuals as polyp-free controls, CA cases, HP
cases, or SSA cases and to define polyp location within
the colorectum. We aimed to determine whether overall
microbial community composition differs between these




We included samples from two independent study popu-
lations: the Centers for Disease Control and Prevention
(CDC) Study of In-home Tests for Colorectal Cancer
(SIT), hereafter referred to as the CDC study, and the
New York University (NYU) Human Microbiome and
Colorectal Tumor study, hereafter referred to as the
NYU study.
The CDC study enrolled 451 participants at the
University of Minnesota/Minnesota Gastroenterology
between December 2012 and July 2014, as part of a
study to evaluate the performance of in-home screening
tests for CRC. The study participants completed fecal
occult blood tests (FOBT) and subsequently under-
went colonoscopy. Eligible participants were individ-
uals 50–75 years old scheduled to have a colonoscopy
for routine screening only, able to read English, and
not currently taking anticoagulant medication. Add-
itionally, participants must not have had more than
one episode of rectal bleeding in the last 6 months, a
positive FOBT in the past 12 months, a colonoscopy
in the past 5 years, a personal history of CRC, polyps,
or inflammatory bowel disease, or a personal or fam-
ily history of familial adenomatous polyposis or her-
editary nonpolyposis colorectal cancer. From the 451
subjects, we further excluded 17 who withdrew from the
study, 4 subjects for whom sequencing failed, and 32 sub-
jects with both conventional and serrated polyp types or
unclassified polyps, resulting in 398 subjects. The CDC
study was approved by the institutional review boards
(IRB) of the University of Minnesota and the CDC, and all
participants provided written consent.
The NYU study enrolled 239 participants from Kips
Bay Endoscopy Center in New York City between June
2012 and August 2014. Eligible participants were
individuals 18 years or older who recently underwent a
colonoscopy, were able to read English, and had not
been on long-term antibiotic treatment. We further ex-
cluded participants that had missing colonoscopy re-
ports (n = 2), personal history of CRC (n = 10) or polyps
(n = 49), inflammatory bowel disease (n = 22), previous
anastomosis (n = 6), personal history of familial aden-
omatous polyposis (n = 1), those with their most recent
colonoscopy reports >3 years prior to stool sample col-
lection (n = 12), and subjects with both conventional and
serrated polyp types or unclassified polyps (n = 12); ex-
clusion due to these non-mutually exclusive criteria re-
sulted in 142 subjects remaining. Of these subjects, 54%
were receiving a colonoscopy for routine screening,
while the remaining 46% had indications for colonos-
copy including abdominal pain, rectal bleeding, change
in bowel habit, or family history of polyps/cancer. The
NYU study was approved by the IRB of NYU School of
Medicine, and all participants provided written consent.
Demographic information assessment
Demographic information (e.g., age, sex, height, weight)
was collected by questionnaire in the CDC and NYU stud-
ies. BMI was categorized as underweight or normal weight
(BMI <25 kg/m2), overweight (25 ≤ BMI < 30 kg/m2), or
obese (BMI ≥30 kg/m2).
Colonoscopy
Colorectal polyps were identified at colonoscopy and
confirmed by pathology. Polyp-free controls were de-
fined as those with no polyps identified during colonos-
copy and no previous history of colorectal polyps.
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Subjects with histologically confirmed normal biopsies
were also included in the control group. CA cases were
defined as those with at least one tubular or tubulovil-
lous adenoma and no other polyps of hyperplastic, SSA,
or unclassified histology. We further classified CAs as
non-advanced if they were <1 cm and had no villous
tissue and as advanced if they were ≥1 cm and/or con-
tained villous tissue [16]. HP cases were defined as hav-
ing at least one HP, with no other polyps of tubular,
tubulovillous, SSA, or unclassified histology. SSA cases
were defined as having at least one SSA, with or without
HP(s), and with no other polyps of tubular, tubulovillous,
or unclassified histology. Proximal polyps were defined
as polyps located in the cecum, ascending colon, hepatic
flexure, transverse colon, or splenic flexure, and distal
polyps were defined as polyps located in the descending
colon, sigmoid colon, or rectum. We classified partici-
pants as either proximal or distal cases based on the lo-
cation of their polyp(s); participants with both proximal
and distal polyps were classified as distal cases.
Stool samples
All subjects collected stool samples onto the two sec-
tions of Beckman Coulter Hemoccult II SENSA® cards
(Beckman Coulter, CA) at home. We have previously
shown that sample collection by this method preserves
stool microbiota composition assessed by 16S rRNA
gene sequencing [17]. Other studies have since con-
firmed this finding, observing that stool collection card
sampling produces reproducible and accurate 16S rRNA
gene-derived microbiota data [18] and exhibits stability
at room temperature for up to 8 weeks [19]. Samples
were collected up to 4 months prior to colonoscopy
(range 3–122 days prior) in the CDC study or up to
3 years after colonoscopy (range 5–1026 days after) in
the NYU study. CDC participant samples were mailed to
a laboratory for fecal occult blood testing within several
days of stool collection; this testing does not impact
stool microbiota composition [18] (see the Quality con-
trol section). After testing, samples were refrigerated at
4 °C until shipment to NYU and, upon arrival, were stored
at −80 °C until analysis (range 7–183 days from sample
collection to receipt by NYU). NYU participant samples
were mailed directly to NYU following at-home collection
and stored immediately at −80 °C until analysis.
Microbiota assay
DNA was extracted from stool using the PowerLyzer
PowerSoil Kit (Mo Bio Laboratory Inc., CA) following
the manufacturer’s protocol. Briefly, we cut the two sec-
tions from the cards containing the stool sample and
placed them into 750 μl bead solution. The fecal mater-
ial in bead solution was lysed using the Powerlyzer (Mo
Bio Laboratory Inc., CA) at 4500 rpm for 45 s. DNA was
collected and eluted using silica columns included with
the PowerLyzer PowerSoil kit. Barcoded amplicons were
generated covering the V4 region of the 16S rRNA gene
using the F515/R806 primer pair [20]. The PCR reaction
was set up using FastStart High Fidelity PCR system,
dNTP pack (Roche, IN) and run as follows: an initial de-
naturing step at 94 °C for 3 min, followed by 25 cycles
of 94 °C for 15 s, 52 °C for 45 s, and 72 °C for 1 min,
and then a final extension at 72 °C for 8 min. PCR
products were purified using Agencourt AMPure XP
(Beckman Coulter Life Sciences, IN) and quantified using
the Agilent 4200 TapeStation (Agilent Technologies, CA).
Amplicon libraries were pooled at equal molar concentra-
tions and sequenced using a 300-cycle (2 × 151 bp) MiSeq
reagent kit on the Illumina MiSeq platform for paired-end
sequencing.
Sequence read processing
Forward and reverse reads were joined using join_paire-
d_ends.py in QIIME [21], allowing a minimum base-pair
overlap of 10 and a maximum of 20% difference in over-
lap region. Sequences were demultiplexed, and poor-
quality sequences excluded, using the default parameters
of QIIME script split_libraries_fastq.py [21]. From the
540 stool samples, we obtained 19,255,455 quality-
filtered 16S rRNA gene sequence reads. Sequence reads
were clustered into de novo operational taxonomic units
(OTUs) at 97% identity, and representative sequence
reads for each OTU were assigned taxonomy based on
fully sequenced microbial genomes (IMG/GG Green-
genes), using QIIME pick_de_novo_otus.py script [21].
Chimeric sequences (identified using ChimeraSlayer
[22]), sequences that failed alignment, and singleton
OTUs were removed. The final dataset retained
18,617,524 sequences (mean ± SD = 34,477 ± 19,417 se-
quence reads/sample) and contained 221,501 OTUs.
Quality control
All samples underwent DNA extraction and sequencing
in the same laboratory, and laboratory personnel were
blinded to case/control status. A total of 3 sequencing
batches were run: 2 for the CDC samples and 1 for the
NYU samples. Quality control samples and negative
controls were included across all sequencing batches.
DNA from 6 stool sample repeats from 4 volunteers
were included in each of 3 sequencing batches (2 CDC,
1 NYU) for a total of 72 quality control samples. In
order to mimic the sample workflow of the CDC study,
1/6 of the quality control stool samples were treated
with Hemoccult SENSA developer (Beckman Coulter,
CA). We calculated intra-class correlation coefficients
(ICCs) for the Shannon diversity index and DESeq2-
normalized counts [23] of abundant bacterial phyla and
genera and found the ICCs to be generally high
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(Additional file 1: Table S1), indicating high similarity of
microbiota profiles within repeated samples from the
same volunteer. Additionally, principal coordinate analysis
(PCoA) showed clustering of the repeated samples from
each volunteer regardless of batch or developer treatment,
indicating good reproducibility (Additional file 1: Figure S1).
Of 9 negative controls (3 in each batch), 6 had zero se-
quence reads, 2 had 1 read, and 1 had 21 reads, indicating
minimal laboratory contamination.
α-Diversity
Within-subject microbial diversity (α-diversity) was
assessed using species richness and the Shannon diver-
sity index, which were calculated in 500 iterations of rar-
efied OTU tables of 4000 sequence reads per sample.
This sequencing depth was chosen to sufficiently reflect
the diversity of the samples (Additional file 1: Figure S2)
while retaining the maximum number of participants for
the analysis (1 control excluded from this analysis due to
sequencing depth = 2088). To compare α-diversity be-
tween cases and controls, we modeled richness and
Shannon index as outcomes in linear regression, adjust-
ing for age, sex, study, and categorical BMI.
Sequence read count filtering
The raw counts of 221,501 de novo OTUs were agglom-
erated to 13 phyla, 28 classes, 51 orders, 103 families,
and 256 genera. We then filtered out low-count taxa by
including only taxa with at least 2 sequence reads in at
least 40 participants, resulting in inclusion of 11 phyla,
20 classes, 24 orders, 51 families, 89 genera, and 2347
OTUs (7 of which were of unassigned taxonomy); this
filtered data was used in all downstream analyses de-
scribed below.
Microbial community types
The stool samples were clustered into community types,
or enterotypes, of similar microbial composition at the
OTU level using the Dirichlet multinomial mixture
(DMM) model [10, 24], implemented using the “Diri-
chletMultinomial” package in R. Fisher’s exact test with
Monte Carlo simulations was used to determine differ-
ences in community types between cases and controls.
Distances and PERMANOVA
β-Diversity (between-sample differences) was assessed at
the OTU level using unweighted and weighted UniFrac
phylogenetic distances [25] and the Jensen-Shannon di-
vergence (JSD). The unweighted UniFrac considers only
OTU presence or absence, while the weighted UniFrac
and JSD take into account OTU relative abundance. Per-
mutational multivariate analysis of variance (PERMA-
NOVA) [26] of the distance matrices, as implemented in
the “vegan” package in R, was used to identify whether
case/control status explains variation in microbial com-
munity composition, adjusting first for study, age, sex,
and categorical BMI.
Differential abundance testing
We used negative binomial generalized linear models, as
implemented in the “DESeq2” [23] package in R, to test
for differentially abundant taxa by case/control status at
phylum-genus levels and at OTU level. This method
models raw count data with a negative binomial distri-
bution and adjusts internally for “size factors” which
normalize for differences in sequencing depth between
samples. Models were adjusted for sex, age, categorical
BMI, and study. DESeq2 default outlier replacement, inde-
pendent filtering of low-count taxa, and filtering of count
outliers were turned off. Taxa models with maximum
Cook’s distance >10 were removed prior to p value adjust-
ment for the false discovery rate (FDR) [27]. We consid-
ered an FDR-adjusted p value (q value) less than 0.10 as
significant.
OTU correlation network
Spearman’s correlation was used to assess relationships
between OTUs that were associated with case/control
status. OTU counts were normalized for DESeq2 [23]
size factors, to account for differences in library size in a
consistent manner to our differential abundance ana-
lysis, prior to correlation analysis. Correlations were cal-
culated independently for the groups under comparison
(e.g., in control + CA samples). Correlation coefficients
with magnitude ≥0.3 were selected for visualization
using the “igraph” package in R.
Results
Participant characteristics
We included a total of 540 colonoscopy-screened indi-
viduals in the current analysis, composed of 323 polyp-
free controls, 144 cases with CAs only, 40 cases with
HPs only, and 33 cases with SSAs (with or without HPs).
CA cases were more likely to be male and tended to be
older than controls (Table 1). HP cases also tended to be
older than controls, while SSA cases did not differ from
controls in sex ratio or age. Of the CAs, 15% (n = 22)
were considered advanced and 38% (n = 55) had polyps
in the distal colon (Table 1). As expected, the majority
of HPs were located in the distal colon (n = 34; 85%) and
the majority of SSAs were located in the proximal colon
(n = 30; 91%) (Additional file 1: Table S2).
Global gut microbiota shifts in relation to colorectal
polyps
We first investigated microbial community diversity of the
participants according to polyp histology and location. CA
cases tended to have lower community diversity than
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controls (richness: p = 0.03; Shannon index: p = 0.09), a
pattern that was consistent for both proximal and distal
CA cases, and particularly apparent in advanced CA cases
(richness: p = 0.004; Shannon index: p = 0.03) (Fig. 1a, b;
Additional file 1: Table S3). Conversely, HP cases had mar-
ginally higher diversity than controls (richness: p = 0.09;
Shannon index: p = 0.07), while community diversity of
SSA cases did not differ from controls (richness: p = 0.96;
Shannon index: p = 0.89), though sample sizes for HP and
SSA groups were small.
We identified 5 microbial community types among the
participants using Dirichlet multinomial mixture models
[24] (Fig. 1c, d), each containing controls, CA cases, HP
cases, and SSA cases. The top 20 OTUs contributing the
most to the Dirichlet components are shown in
Additional file 1: Figure S3; OTUs from Prevotella copri (in-
creased normalized abundance in community type 5), Fae-
calibacterium prausnitzii (lower normalized abundance in
community type 2), and an unclassified Bacteroides species
(increased normalized abundance in community type 1)
were the highest contributors. While the distribution of
these community types did not differ significantly by hist-
ology (Fig. 1e; Fisher’s exact test p= 0.22), we observed a
marginally significant difference in community-type distri-
bution by CA polyp location (Fig. 1f; Fisher’s exact test p=
0.09) and by CA non-advanced or advanced classification
(Fig. 1g; Fisher’s exact test p= 0.08). Compared with con-
trols, a higher percentage of distal CA cases were members
of community type 1 and fewer were members of commu-
nity types 3 and 4, while a higher percentage of advanced
CA cases were members of community type 2 and fewer
were members of community types 3 and 5. Direct compari-
son of distal CA cases to controls revealed a significant dif-
ference in community type distribution between the two
groups (Fisher’s exact test p= 0.01), though direct compari-
son of advanced CA cases to controls did not (p= 0.20).
Table 1 Demographic and polyp characteristics of the study participants
Controls CA cases HP cases SSA cases
N 323 144 40 33
Male, % 47.1 67.4** 52.5 54.5
Age (years), mean ± SD 61.3 ± 7.2 63.1 ± 6.6* 64.4 ± 7.5* 63.1 ± 7.0
Whitea, % 94.4 95.0 92.5 97.0
Family history of cancerb, % 25.2 29.1 41.0 25.0
BMI categoryc, %
Under or normal-weight (BMI <25 kg/m2) 39.9 31.2 32.5 24.2
Overweight (25 ≤ BMI < 30 kg/m2) 38.7 43.1 42.5 45.5
Obese (BMI ≥30 kg/m2) 21.4 25.7 25.0 30.3
Study, %
CDC 75.5 70.1 60.0 87.9
NYU 24.5 29.9 40.0 12.1
Polyp histologyd, %
TA <1 cm only 84.0
TA ≥1 cm, TVA, or TA and TVA only 15.3
Hyperplastic only 100.0
SSA only 81.8
SSA and hyperplastic only 18.2
Polyp locatione, %
Proximal 60.4 15.0 90.9
Distal 38.2 85.0 9.1
CA conventional adenoma, HP hyperplastic polyp, SSA sessile serrated adenoma
*p < 0.05, **p < 0.001, different from controls by Wilcoxon rank-sum test or Chi-squared test for continuous or categorical variables, respectively
an = 4 were missing race
bn = 7 were missing family history
cThose missing BMI (CDC n = 1, NYU n = 3) were re-coded as the median (CDC 27 kg/m2, NYU 25 kg/m2) in order to retain sample size in covariate
adjusted analyses
dTA tubular adenoma, TVA tubulovillous adenoma, SSA sessile serrated adenoma, n = 1 subject with a TA could not be classified by size, so conventional adenoma
percentage will not sum to 100%
eProximal: polyps only in the cecum, ascending colon, hepatic flexure, transverse colon, or splenic flexure; distal: any polyp located in the descending colon,
sigmoid colon, or rectum; see Additional file 1: Table S2 for further breakdown by specific location; n = 2 subjects with CAs could not be classified by location, so
CA percentage will not sum to 100%
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Fig. 1 (See legend on next page.)
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PERMANOVA analyses of between-sample distances
adjusting for covariates largely supported the findings
from the community-type analyses: stool microbial com-
position of distal CA cases and advanced CA cases tended
to differ from controls (distal vs. controls: unweighted
UniFrac p = 0.02, weighted UniFrac p = 0.05, JSD p = 0.11;
advanced vs. controls: unweighted UniFrac p = 0.002,
weighted UniFrac p = 0.02, JSD p = 0.02), while the other
case groupings (all CA cases, proximal CA cases, non-
advanced CA cases, HP cases, and SSA cases) did not dif-
fer significantly from controls (all p ≥ 0.10). We did not
further classify CA cases into joint location × advanced
categories due to sample size restrictions (n = 7 in the
distal advanced group).
Taxa associated with conventional adenomas
We next explored taxonomic signatures of the gut
microbiota by polyp histology and location using
negative binomial generalized linear models [23]. We
identified 25 OTUs that were differentially abundant
(q < 0.10) between CA cases and controls (Fig. 2;
Additional file 1: Table S4); 20 of these, all from class
Clostridia, had decreased normalized abundance in
CA cases compared to controls. Conversely, 1 OTU
(See figure on previous page.)
Fig. 1 α-Diversity and community types of colonoscopy-screened participants. a Violin plots of species richness and b Shannon diversity index by polyp
histology (controls n= 322, CA cases n= 144, HP cases n= 40, SSA cases n= 33), location (distal CA n= 55, proximal CA n= 87), and advancement level (non-
advanced CA n= 121, advanced CA n= 22). These indices were calculated for 500 iterations of rarefied (4000 sequences per sample) OTU tables, and the
average over the iterations was taken for each participant (1 control excluded due to sequencing depth = 2088). p values from multiple linear regression are
shown. c Fitting to the DMM [24, 56] model indicates optimal classification into 5 community types. d Principal coordinate analysis of Jensen-Shannon
divergence values between participants, colored by community type. Green community type 1, blue type 2, purple type 3, yellow type 4, red type 5.
e Distribution of the community types in groups distinguished by histology, f location, or g advancement level. p value from Fisher’s exact test with
Monte Carlo simulation is shown. CAs conventional adenomas, HPs hyperplastic polyps, SSAs sessile serrated adenomas
Fig. 2 Heatmaps of OTUs that were differentially abundant between colorectal polyp cases and controls. All OTUs with q < 0.10 for comparisons of
any case group (all CA, non-advanced CA, advanced CA, distal CA, proximal CA, HP, SSA) vs. controls are included in the figure. a Heatmap shows fold
change from controls in the DESeq2 models, with white star indicating q < 0.10 for the comparison. b Heatmap shows OTU counts in each participant.
For display, counts were normalized for DESeq2 size factors and log2 transformed after adding a pseudocount of 1. n = 1 and n = 2 CA cases were
missing advanced status or location information, respectively. CAs conventional adenomas, HPs hyperplastic polyps, SSAs sessile serrated adenomas
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each from Actinomyces, Streptococcus, Lactobacillus zeae,
Dorea, and an unclassified Lachnospiraceae genus had in-
creased normalized abundance in CA cases. Many of the
decreased Clostridia OTUs formed a correlation network,
while the increased Actinomyces and Streptococcus OTUs
were also inter-correlated (Fig. 3a). At broader levels of
taxonomic classification, the observed OTU level associa-
tions manifested in an observed increased normalized
abundance of class Bacilli and genera Streptococcus,
































































Enriched in distal CA cases
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Firmicutes; Bacilli Firmicutes; Clostridia Bacteroidetes Actinobacteria
Fig. 3 Microbial community ecology in controls and conventional adenoma cases. Correlation network of OTUs differentially abundant between
a controls and all CA cases, b controls and distal CA cases, and c controls and proximal CA cases. Spearman’s correlation coefficients were
estimated using counts (normalized for DESeq2 size factors) and calculated among the samples under comparison. Lines shown between OTUs
indicate Spearman’s correlation ≥0.3 (green) or ≤-0.3 (red). Direction of enrichment in relation to all CA/distal CA/proximal CA cases vs. controls
was determined from DESeq2 models. OTUs are colored according to family membership. Line thickness represents strength of the correlation, in
steps of 0.3–0.4 (thinnest), 0.4–0.5, 0.5–0.6, 0.6–0.7, and >0.7 (thickest). CA conventional adenoma
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(Table 2). Analysis of broader taxonomic classification
levels also revealed that CA cases exhibited greater nor-
malized abundance than controls of class Gammaproteo-
bacteria, its order Enterobacteriales, and genera
Corynebacterium (class Actinobacteria), Peptoniphilus,
and Phascolarctobacterium (class Clostridia), and de-
creased normalized abundance of genus Coprobacillus
(class Erysipelotrichi), and unknown genera within family
Mogibacteriaceae (class Clostridia) and order RF39 (class
Mollicutes) (Table 2; Additional file 1: Table S5).
CAs were further classified as proximal (n = 87) or dis-
tal (n = 55) and as non-advanced (n = 121) or advanced
(n = 22), in order to explore taxonomic signatures associ-
ated with these sub-groups. Many OTUs from class
Clostridia had decreased normalized abundance in distal
CA cases compared to controls, including OTUs from
families Ruminococcaceae, Clostridiaceae, Christensenel-
laceae, and Mogibacteriaceae (Fig. 2; Additional file 1:
Table S6). These OTUs formed a positive correlation
network with each other (Fig. 3b). One OTU from
Streptococcus and one from Lachnospiraceae had in-
creased normalized abundance in distal CA cases, and
the OTU from Lachnospiraceae was inversely correlated
with several of the decreased Clostridia OTUs (Fig. 3b).
These OTU level associations manifested in associations
at broader taxonomic levels, including significantly de-
creased normalized abundance of class Clostridia and
families Mogibacteriaceae, Christensenellaceae, and
Clostridiaceae in distal CA cases compared to controls
(Additional file 1: Table S6). Proximal CA cases also had
Table 2 Differentially abundanta classes and genera between controls and CA cases, HP cases, and SSA cases











Firmicutes; Bacilli 506.3 2.11 (1.6, 2.78) 2.45E−06 1.23 (0.78, 1.94) 1.00 0.79 (0.49, 1.3) 0.79
Firmicutes; Erysipelotrichi 305.8 0.92 (0.79, 1.07) 0.57 1.1 (0.85, 1.41) 1.00 0.68 (0.52, 0.89) 0.09









1.0 3.73 (1.88, 7.4) 0.002 0.78 (0.28, 2.22) 0.99 0.86 (0.3, 2.5) 0.98
Firmicutes; Bacilli; Lactobacillales;
Streptococcaceae; Streptococcus
422.2 2.38 (1.76, 3.21) 1.35E−06 1.26 (0.78, 2.05) 0.99 0.72 (0.43, 1.21) 0.65
Firmicutes; Clostridia; Clostridiales;
NA; NAd
2624.0 1.44 (1.26, 1.65) 6.31E−06 1.18 (0.94, 1.47) 0.92 0.98 (0.77, 1.25) 0.98
Firmicutes; Clostridia; Clostridiales;
[Mogibacteriaceae]; NAd
16.2 0.78 (0.65, 0.94) 0.06 0.85 (0.63, 1.15) 0.99 0.89 (0.65, 1.22) 0.88
Firmicutes; Clostridia; Clostridiales;
[Tissierellaceae]; Peptoniphilus
1.6 3.41 (1.83, 6.35) 0.002 0.55 (0.21, 1.46) 0.99 0.85 (0.32, 2.28) 0.98
Firmicutes; Clostridia; Clostridiales;
Lachnospiraceae; Anaerostipes
45.7 1.23 (0.98, 1.54) 0.30 1.96 (1.36, 2.84) 0.03 1.02 (0.69, 1.52) 0.98
Firmicutes; Clostridia; Clostridiales;
Lachnospiraceae; Dorea
216.1 1.19 (1.05, 1.35) 0.06 1.09 (0.88, 1.34) 0.99 1 (0.8, 1.25) 0.99
Firmicutes; Clostridia; Clostridiales;
Veillonellaceae; Phascolarctobacterium
115.4 1.91 (1.24, 2.96) 0.04 1.12 (0.57, 2.22) 0.99 0.85 (0.41, 1.76) 0.98
Firmicutes; Erysipelotrichi; Erysipelotrichales;
Erysipelotrichaceae; Coprobacillus
10.8 0.59 (0.39, 0.88) 0.07 0.36 (0.19, 0.68) 0.07 1.03 (0.53, 2.01) 0.98
Proteobacteria; Betaproteobacteria;
Burkholderiales; Alcaligenaceae; Sutterella
430.2 2.06 (1.52, 2.78) 8.60E−05 0.84 (0.52, 1.37) 0.99 0.97 (0.58, 1.65) 0.98
Tenericutes; Mollicutes; RF39; NA; NAd 36.4 0.42 (0.22, 0.78) 0.06 1.1 (0.44, 2.77) 0.99 1.06 (0.4, 2.81) 0.98
CA, conventional adenoma, HP hyperplastic polyp, SSA sessile serrated adenoma
aDifferential abundance was detected by the “DESeq” function in the DESeq2 package. All classes and genera with an FDR-adjusted q < 0.10 are included in the
table. Models were adjusted for sex, age, study, and categorical BMI. See Additional file 1: Table S5 for comparisons at the phylum, order, and family level
bCounts were normalized by dividing raw counts by DESeq2 size factors
cFDR-adjusted p value. FDR adjustment was conducted at each level (i.e., class, genus) separately
dNA: unclassified genus
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some differentially abundant OTUs from controls,
including Dorea and Peptoniphilus OTUs (increased
normalized abundance in proximal CA cases), and
Bacteroides, Coprococcus, and unclassified Lachnospira-
ceae and Ruminococcaceae OTUs (decreased normalized
abundance in proximal CA cases) (Fig. 2; Additional file
1: Table S6); most of these OTUs were uncorrelated with
one another (Fig. 3c). Analysis at broader levels of
taxonomic classification revealed additional differences
between proximal CA cases and controls that were not
all apparent at the OTU level; similar to the all CA case
analysis, proximal CA cases exhibited greater normal-
ized abundance than controls of classes Bacilli and
Gammaproteobacteria, order Enterobacteriales, and
genera Actinomyces, Corynebacterium, Streptococcus,
Dorea, Peptoniphilus, and Phascolarctobacterium,
among others (Additional file 1: Table S6).
Although the overall microbiota composition of
advanced CA cases was significantly different from
controls in the global analysis, we observed only one
differentially abundant OTU (from genus Peptoniphi-
lus, q < 0.10) between advanced CA cases and controls
(Fig. 2; Additional file 1: Table S7); this is likely an
issue of low power as the sample size of advanced
CA cases was small (n = 22). However, both non-
advanced and advanced CA cases exhibited similar di-
rections of fold change in OTU normalized abun-
dance from controls (Fig. 2), indicating similarity
between the two groups. At broader taxonomic classifica-
tion levels, advanced CA cases exhibited greater normalized
abundance than controls of genera Actinomyces, Corynebac-
terium, Peptoniphilus, Porphyromonas, and Haemophilus
and lower normalized abundance than controls of genera
Lachnospira, Lachnobacterium, and unclassified genera
from Mogibacteriaceae, Christensenellaceae, and RF39
(Additional file 1: Table S7). Non-advanced CA cases, mak-
ing up the majority of all CA cases, exhibited similar differ-
entially abundant taxa from controls as in the all CA case
analysis.
Taxa associated with hyperplastic polyps and SSAs
We identified few differentially abundant taxa between
HP cases or SSA cases and controls (q < 0.10). HP cases
had increased normalized abundance of Lactobacillus
zeae and decreased normalized abundance of an uniden-
tified OTU in family Lachnospiraceae (Fig. 2; Additional
file 1: Table S4). HP cases also had decreased normalized
abundance of class Gammaproteobacteria, order Entero-
bacteriales, and genus Coprobacillus and increased nor-
malized abundance of genus Anaerostipes, compared to
controls (Table 2; Additional file 1: Table S5). SSA cases
had decreased normalized abundance of class Erysipelo-
trichi (Table 2); however, no other taxa (phylum-genus
levels or OTU level) were identified as differentially
abundant (q < 0.10) between SSA cases and controls.
Sensitivity analysis
We conducted our main analysis excluding participants
(n = 5) who collected their stool sample <2 weeks after
their colonoscopy, in order to ensure results were not
biased by effects of colon preparation and colonoscopy
on the microbiota (Additional file 1: Table S8). We also
conducted our main analysis excluding participants who
had taken antibiotics within 30 days prior to sample col-
lection (n = 19 from the NYU study), in order to ensure
results were not biased by effects of antibiotics on the
microbiota (antibiotic usage information was not avail-
able in the CDC study) (Additional file 1: Table S9). Ex-
cluding these participants groups did not substantially
impact findings.
Discussion
In this large study of colonoscopy-screened adults, we
found that CA-associated changes in gut microbiota di-
versity and composition in relation to controls depended
on the severity and location of the adenoma. More spe-
cifically, advanced CA cases had the greatest reduction
in community diversity compared to controls, while dis-
tal or advanced CA cases differed significantly in micro-
biota composition from controls. Such differences were
not observed for subjects with hyperplastic polyps or
SSAs. Our results indicate that gut bacteria may play
distinct roles in the development of site-specific histo-
logically different polyp types. To our knowledge, this is
the first study to simultaneously consider different polyp
histologies and locations and the largest study of the gut
microbiota and colorectal polyps to date.
Our finding of reduced species richness and diversity
in CA cases, particularly advanced CA cases, is consist-
ent with observations in CRC from our group in the
USA [9] and from another group in China [28]. De-
creased gut microbial diversity, often observed in other
diseases including obesity [29] and inflammatory bowel
diseases [30, 31], is likely indicative of underlying bacter-
ial dysbiosis, possibly due to domination by opportunis-
tic pathogenic bacteria and/or loss of commensal
bacteria. While other reports of colorectal polyp [32–35]
and cancer [10, 36–38] showed mixed results in regard
to community diversity, including findings of no differ-
ences in diversity or increased diversity in cases, sample
sizes for these studies were small (N for cases ranged
from 7 to 53). These differing results may be related to
limited power or to the specific bacterial drivers or path-
ogens present in each unique study population.
Our observation of global OTU-level composition
shifts in distal, but not proximal, CA cases compared to
controls is likely due to stool being a better proxy for
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the bacterial communities of the distal colon than of the
proximal colon [39]. This was proposed in a recent
metagenomic study of colorectal cancer, in which
carcinoma-associated bacterial genes were more abun-
dant in stool of distal CRC cases than proximal CRC
cases [10]. Additionally, there is evidence that mucosal
bacterial biofilms play a role in proximal, but not distal,
CRCs [40], further suggesting that bacteria are involved
in proximal tumor formation, but that stool may be an
inappropriate sample to test their involvement. However,
despite the lack of global OTU-level shifts in proximal
CA cases compared to controls, we did observe a taxo-
nomic signature for proximal CA cases at broader levels
of taxonomic classification; further, this signature dif-
fered from that of distal CA cases. This finding suggests
that the role bacteria play in CA development may differ
between proximal and distal colon sites. There are
known molecular distinctions between proximal and dis-
tal CRCs, most notably that proximal CRCs are more
likely to be hypermethylated and to have elevated muta-
tion rates [41]. Additionally, the luminal environment
differs between proximal and distal colon sites: there are
high levels of easily fermentable carbohydrate substrates
in the proximal colon, which decrease distally through
the colon [39, 42]; the mucus layer increases in thickness
distally through the colon [42]; the number of bacterial
cells increases distally through the colon [43]; and im-
mune activity decreases distally through the colon [44].
These differences can result in site-specific bacterial
communities and processes, which may contribute to
CA development in distinct ways.
A major shift in stool microbiota composition observed
for CA cases was the depleted normalized abundance of a
network of Clostridia OTUs from families Ruminococca-
ceae, Clostridiaceae, and Lachnospiraceae; this was par-
ticularly apparent in distal CA cases, in which the class
Clostridia was significantly depleted. Members of these
Clostridia families have in common the capacity to gener-
ate butyrate from fermentation of non-digestible plant fi-
bers [45], which is beneficial to colonic health [46].
Depletion of butyrate-producing bacteria in the distal
colon, where carbohydrate substrate supply is already
compromised [39, 42], may allow for adenoma growth.
The decreased normalized abundance of Clostridia we
have observed here is consistent with our previous study
of CRC, in which the relative abundance of class Clos-
tridia was depleted in stool samples of CRC cases com-
pared to controls [9]. Other studies have also found
decreased relative abundance of butyrate-producing bac-
teria in adenoma [33, 47, 48] and CRC [36, 37], supporting
the protective effects of butyrate against CRC.
The taxonomic signature of proximal CA cases was
not apparent at the OTU-level, though distinct patterns
emerged at broader levels of taxonomic classification;
this is perhaps because the stool microbiota are a poor
proxy for the microbiota of the proximal colon, thus re-
ducing power to detect OTU-level differences between
proximal CA cases and controls. Proximal CA cases ex-
hibited greater normalized abundance than controls of
classes Bacilli and Gammaproteobacteria, order Entero-
bacteriales, and genera Actinomyces, Corynebacterium,
Streptococcus, Dorea, Peptoniphilus, and Phascolarcto-
bacterium; some of these bacteria may be candidate
drivers of the CA pathway in the proximal colon. Some
results from other studies are similar to these findings
(though none of these studies have distinguished aden-
omas by location): the genera Dorea [48], Phascolarcto-
bacterium [48], and Streptococcus [32, 33, 49], as well as
genera within the Enterobacteriaceae family of Gamma-
proteobacteria [32, 34, 35, 48, 49], were elevated in mu-
cosal or stool samples from adenoma cases compared to
controls. Additionally, the Enterobacteriaceae family and
Actinomycetales order have been highlighted as potential
CRC driver bacteria, based on their over-representation
in off-tumor compared to on-tumor paired samples from
CRC patients [12]. Members of Enterobacteriaceae are
known to cause inflammation in the gastrointestinal
tract and could contribute to CRC via inflammatory
mechanisms [12, 50]. Interestingly, a recent report on
CRCs found that invasive polymicrobial bacterial bio-
films were a key feature of proximal colon tumors, but
not distal tumors [40]. This study implicated the
organization, rather than composition, of mucosal
communities in proximal CRC development. It will be
important for future studies to examine the mucosal
communities of proximal CAs and to determine the mi-
crobial organizational and/or compositional factors asso-
ciated with their presence.
The observation that the stool microbial composition
of SSA cases was similar to that of controls was unex-
pected, since an animal model [51] and human study
[52] suggest involvement of host microbiota in serrated
polyp development. We did observe a decrease in the
Erysipelotrichi class in SSA cases; this class has been as-
sociated with colon mucus barrier impenetrability in
mice [53] and may play a protective role in SSA develop-
ment. Our lack of other findings is likely related to low
power due to the small sample size of SSA cases and the
proximal location of SSAs. Another potential explan-
ation for this finding is the possibility that bacteria may
initiate CRC via a mechanism related to the conven-
tional pathway, but not serrated pathway, such as by in-
ducing chromosomal instability [54].
Strengths of this study include the large sample size, the
histologic and location classification of polyps for all cases,
the inclusion of polyp-free controls, and the comprehen-
sive bacterial profiling using 16S rRNA gene sequencing.
However, this study also has several limitations. We did
Peters et al. Microbiome  (2016) 4:69 Page 11 of 14
not examine colorectal mucosal samples; while easily ob-
tainable stool samples are important for developing tools
for risk stratification and screening for CRC [38, 47], mu-
cosal samples are important from a prevention standpoint,
as they allow for better identification of bacteria associated
with adenoma. Assessment of differences in the stool
microbiota between polyp cases and polyp-free controls
may provide insight into systematic differences in the gut
microbiota between these groups that may contribute to
polyp development. Future studies incorporating mucosal
samples will be able to better pinpoint specific mucosal-
associated bacteria responsible for polyp initiation and
growth. Further limitations are the mostly white study popu-
lation, limiting generalizability to other racial groups, the
lack of antibiotic usage information in the CDC study, and
the cross-sectional design, which does not allow us to estab-
lish the temporality of the bacteria-adenoma relationship.
Conclusions
Due to the different molecular origins and etiologies of
CRC, which may vary by colon site [44], it is critically
important to consider that the role bacteria play in aden-
oma development may differ by polyp histology and lo-
cation, as our results suggest. Although evidence is
mounting for a role of driver bacteria in colorectal car-
cinogenesis, it is likely that different bacterial drivers can
confer the same risk for CRC [12]. Bacterial drivers may
differ between patients and populations and between
polyp histologies and locations. The possibility that there
are multiple population-specific, histology-specific, and
site-specific bacterial drivers of CRC highlights the need
for additional, larger studies in different populations,
taking into consideration polyp histology and location,
in order to fully characterize the broad array of potential
bacterial drivers of CRC, as well as potential protective
bacteria, and to identify their functions. Identification of
the bacterial drivers of CRC may lead to development of
targeted prophylactic therapies. Identification of benefi-
cial bacteria depleted in adenomas may lead to imple-
mentation of dietary interventions or probiotic/prebiotic
therapies to promote their regrowth and recolonization
[55]. Thus, continued study of the early stages of the
adenoma-carcinoma sequence may lead to actionable
means for CRC prevention.
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